Allergan Just Announced Two Significant Deals

Allergan (AGN) - Get Report is out with two important deals on Monday, just as the J.P. Morgan Healthcare Conference begins. First, Allergan announced a licensing agreement with Assembly Biosciences (ASMB) - Get Report in a deal valued at $50 million. Allergan will hold the rights for its microbiome gastrointestinal development programs. "The Microbiome -- the microbial populations that colonize the human body -- is rapidly gaining prominence in numerous fields of research relevant to Allergan's key areas of focus, including GI disorders," said David Nicholson, Chief R&D Officer, Allergan. Secondly, Allergan has purchased an exclusive option to purchase Lysosomal Therapeutics. The cost was not released. Allergan can acquire the company once a trial of its Parkinson's disease drug has been completed.